| |JANUARY 20268SUN PHARMA ROLLS OUT UNLOXCYT WITH UPDATED FDA LABEL IN USMAX HEALTHCARE COLLABORATES WITH GOOGLE FOR DIRECT APPOINTMENT BOOKINGMax Healthcare collaborates with Google to make hospital appointment booking faster and simpler for patients across India.Starting today, people searching for Max Hospitals, doctors, or medical specialties on Google Search and Google Maps can book appointments directly from the results page, without extra steps or redirects to third-party sites.The new capability is the Appointments Redirect of Google. An obvious Book Online button has now been introduced in the related searches. On a single click, the users are redirected directly to the formal appointment booking page of Max Healthcare. This eliminates friction, reduces waiting time, and assists patients to eliminate unverified platforms that lead to confusion most of the time.The signed redirection will make sure that patients are provided with the correct and up to date information at all stages. The system also ensures trust by directing users to the verified digital channels of Max Healthcare only, and the experience of booking will be enhanced in this way as well.Commenting on the collaboration, Anas Abdul Wajid, Senior Director - Chief Sales and Marketing Officer, Max Healthcare, said, "A large number of patients begin their healthcare journey through a search on Google. Our goal is to make their journey from search to appointment as simple as possible.""By enabling direct booking via Google, we are helping people save valuable time, avoid confusion, and confidently access our trusted clinical services. Importantly, this initiative is aligned with our wider efforts towards digital transformation to build a more seamless, connected, and patient-centric healthcare ecosystem."The feature is operational in all the Max Healthcare facilities, which provides a uniform booking experience in the country. As Max Healthcare collaborates with Google, another step toward the creation of a more robust digital healthcare ecosystem based on access, trust, and patient convenience is made by the hospital chain. POTOP STORIESSun Pharmaceutical Industries has started the commercial launch of its cancer medication, Unloxcyt, in the United States market.This is a significant development for the Indian pharmaceutical company in the international market for cancer treatment.The medication, known by the brand name Unloxcyt (cosibelimab-ipdl) in the market, has been made available for prescription by doctors for the treatment of adults who have metastatic or locally advanced cutaneous squamous cell carcinoma (aCSCC) and cannot receive curative therapy.The launch has come after the United States FDA approved an updated labeling for Unloxcyt based on long-term clinical data that has shown durable responses with a good tolerability profile. The results of the pivotal studies have shown meaningful objective responses with sustained disease control in a number of patients, supporting the drug's utility for advanced skin cancer."Unloxcyt is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile for a group of aCSCC patients who traditional would struggle to strike that therapeutic balance," said Richard Ascroft, CEO , Sun Pharma North America.Sun Pharma introduced support services for patients and healthcare practitioners, which not only shows the commitment to enhance care delivery from Day One but is an important aspect to consider.Industry observers believe that Unloxcyt's foray into the U.S. market, apart from meeting an urgent and unserved need for patients with advanced skin cancers, will further enhance Sun Pharma's specialty offerings as they continue to diversify and move away from their traditional focus on generics and into innovative and high-value products. PO
< Page 7 | Page 9 >